IL6 and scleroderma: Regarding the good safety profiles of currently available CD47- and IL-6–blocking agents, we believe that our study gives enough evidence to safely try combined immunotherapy with CD47 and IL-6 inhibition in patients with highly fibrotic and stable, nonprogressive scleroderma.